This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Ferrous gluconate oral

Updated 2 Feb 2023 | Oral iron


Oral formulations containing ferrous gluconate

Drugs List

  • ferrous gluconate 300mg tablets
  • Therapeutic Indications


    Prophylaxis of iron deficiency anaemia
    Treatment of iron deficiency anaemia



    1200 mg to 1800 mg (4 to 6 tablets) daily in divided doses before food

    600 mg (2 tablets) daily before food


    1200 mg to 1800 mg (4 to 6 tablets) daily in divided doses before food

    600 mg (2 tablets) daily before food

    Care should be taken as the preparation may be constipating in older patients.


    Children 12 years and above
    Prophylactic and therapeutic
    See Dosage; Adult

    Children 6 to 12 years
    Prophylactic and therapeutic
    300 mg to 900 mg (1 to 3 tablets) daily

    Additional Dosage Information

    The haemoglobin concentration should rise by about 100 to 200 mg/100 mL (1 to 2 g/litre) per day or 2 g/100 mL (20 g/litre) over 3 to 4 weeks. When the haemoglobin is in the normal range, treatment should be continued for a further 3 months to replenish the iron stores.


    Children under 6 years
    Inflammatory bowel disease
    Peptic ulcer
    Repeated blood transfusions
    Ulcerative colitis

    Precautions and Warnings

    Gastrointestinal diverticula
    Gastrointestinal stenosis
    Glucose-galactose malabsorption syndrome
    Haemolytic anaemia
    Hereditary fructose intolerance

    Exclude non-iron deficiency anaemia
    Some formulations contain Ponceau 4R (E124)-may cause allergic reactions
    Some formulations contain sucrose
    Advise patient stools may be discoloured
    Advise patient to take after food to reduce gastro-intestinal disturbances

    Pregnancy and Lactation


    No adverse effects have been reported during pregnancy, at the recommended dose.

    The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( ) or if this is unavailable at the backup site ( ).


    No adverse effects have been reported during breastfeeding at the recommended dose.

    Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
    Specialist advice is available from the UK Drugs in Lactation Advisory Service at

    Side Effects

    Allergic reaction
    Discolouration of stools
    Epigastric pain
    Faecal impaction
    Gastro-intestinal symptoms


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: October 2014

    Reference Sources

    Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press. Accessed on 19 September 2014.

    Paediatric Formulary Committee. BNF for Children (online) London: BMJ Group, Pharmaceutical Press, and RCPCH Publications. Accessed on 19 September 2014.

    Summary of Product Characteristics: Ferrous Gluconate 300mg tablets. Kent Pharmaceuticals Ltd. Revised June 2014

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.